Binds Plasma Protein, Serum Protein, Or Fibrin (e.g., Clotting Factor, Fibrinolytic Factor, Complement Factor, Immunoglobulin, Apolipoprotein, Etc.) Patents (Class 530/388.25)
-
Patent number: 8236317Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: GrantFiled: January 17, 2012Date of Patent: August 7, 2012Assignee: Genentech, Inc.Inventors: Michael S. C. Fung, William N. C. Sun, Cecily R. Y. Sun
-
Patent number: 8236316Abstract: The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.Type: GrantFiled: November 21, 2008Date of Patent: August 7, 2012Assignees: Oregon Health & Science University, Vanderbilt UniversityInventors: Andras Gruber, Erik Ian Tucker, Stephen Raymond Hanson, David Gailani
-
Patent number: 8211432Abstract: Disclosed are antibodies that block the binding of fibronectin protein to fibronectin. Also disclosed are site specifically-mutated and truncated peptide epitopes derived from the fnbA and fnbB genes of Staphylococcus aureus, the fnbA and fnbB genes of Streptococcus dysgalactiae, and the sfb gene of Streptococcus pyogenes, and nucleic acid segments encoding these peptides and epitopes. The anti-(fibronectin binding site) antibodies, peptides and epitopes that give rise to antibodies that block the binding of fibronectin binding proteins to fibronectin, and DNA segments encoding these proteins and are of use in various screening, diagnostic and therapeutic applications including active and passive immunization and methods for the prevention of streptococcal and staphylococcal colonization in animals or humans. These. DNA segments and the peptides derived therefrom are proposed to be of use directly in the preparation of vaccines and also for use as carrier proteins in vaccine formulations.Type: GrantFiled: October 31, 2006Date of Patent: July 3, 2012Assignees: University of Manitoba, Universita' Degli Studi di Pavia, Texas A&M University SystemInventors: Magnus Höök, Joseph M. Patti, Karen L. House-Pompeo, Pietro Speziale, Danny Joh, Martin J. McGavin
-
Patent number: 8206716Abstract: The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated by excessive or uncontrolled production of C5a. The inhibitor molecules are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a.Type: GrantFiled: January 24, 2008Date of Patent: June 26, 2012Assignee: Genentech, Inc.Inventors: Michael Fung, Meisheng Lu, William N. C. Sun, Cecily R. Y. Sun
-
Patent number: 8187604Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.Type: GrantFiled: January 14, 2011Date of Patent: May 29, 2012Assignee: Genentech, Inc.Inventors: Ling-Ling An, Sek Chung Fung, Robert F. Kelley, Henry B. Lowman, Sanjaya Singh, Herren Wu
-
Patent number: 8129129Abstract: The present invention describes a method for diagnosing tumors of the reproductive organs which is characterized by determination of the afamin content in a sample of a body fluid or in a tissue sample, wherein a tumor is diagnosed if the afamin content in the sample is decreased compared to the afamin content in a sample from a person without a tumor of the reproductive organs.Type: GrantFiled: March 12, 2010Date of Patent: March 6, 2012Assignee: Vitateq Biotechnology GmbHInventor: Hans Dieplinger
-
Patent number: 8124742Abstract: The invention includes Rh(D) binding proteins, including antibodies, and DNA encoding such proteins. Methods of generating such proteins and DNAs are also included.Type: GrantFiled: February 22, 2005Date of Patent: February 28, 2012Assignee: The Trustees of the University of PennsylvaniaInventor: Donald L. Siegel
-
Patent number: 8124090Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: GrantFiled: April 6, 2011Date of Patent: February 28, 2012Assignee: Genentech Inc.Inventors: Michael S. C. Fung, William N. C. Sun, Cecily R. Y. Sun
-
Patent number: 8114966Abstract: The present invention relates to passive immunization for treating or preventing atherosclerosis using an isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B in the manufacture of a pharmaceutical composition for therapeutical or prophylactical treatment of atherosclerosis by means of passive immunization, as well as method for preparing such antibodies, and a method for treating a mammal, preferably a human using such an antibody to provide for passive immunization.Type: GrantFiled: October 27, 2008Date of Patent: February 14, 2012Assignee: Forskarpatent I SYD ABInventors: Jan Nilsson, Roland Carlsson, Jenny Bengtsson, Leif Strandberg
-
Patent number: 8105597Abstract: The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarily determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prevention of conditions and diseases associated with A?, including Alzheimer's disease. Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like.Type: GrantFiled: July 17, 2009Date of Patent: January 31, 2012Assignee: Applied Molecular Evolution, Inc.Inventors: Julian Davies, Ying Tang, Jeffry Dean Watkins
-
Publication number: 20110300641Abstract: Several aspects of this invention relate to diagnosis of diabetic states in a mammal using protein isoforms. In some aspects, it relates to a method for determining the diabetic state of a mammal. This method can include, for example, (a) measuring the serum concentration of one or more protein isoforms, (b) analyzing the serum concentration of the one or more protein isoforms, and (c) determining the diabetic state of the mammal. Other aspects include kits used to perform the method. Further aspects are the isolated protein isoforms themselves, and their methods of isolation.Type: ApplicationFiled: March 27, 2009Publication date: December 8, 2011Applicant: OHIO UNIVERSITYInventors: John J. Kopchick, Shigeru Okada, Sudha Sankaran
-
Publication number: 20110294145Abstract: The present invention provides antibodies that differentially react with allelic variants of a polymorphic protein, methods of identifying same, an antigen binding fragment comprised therein, proteins, cells, viral particles, compositions, and kits comprising same. The invention also provides methods for determining a haptoglobin type of a subject and methods for testing a subject for susceptibility to diabetic complications.Type: ApplicationFiled: June 11, 2009Publication date: December 1, 2011Inventors: Jacob Victor, Noah Berkowitz, Andrew Levy
-
Patent number: 8067002Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.Type: GrantFiled: October 31, 2007Date of Patent: November 29, 2011Assignee: Genentech, Inc.Inventors: Ling-Ling An, Sek Chung Fung, Robert F. Kelley, Henry B. Lowman, Sanjaya Singh, Herren Wu
-
Patent number: 8063180Abstract: The invention relates to antibodies directed against F1+2, to the preparation and use thereof, especially in therapy and diagnosis. The antibodies bind to an epitope on the N-terminal half of the F2 fragment of prothrombin.Type: GrantFiled: November 16, 2009Date of Patent: November 22, 2011Assignee: Seimens Healthcare Diagnostics Products GmbHInventors: Stefan Teigelkamp, Konrad Braun
-
Patent number: 8062887Abstract: The present invention provides a monoclonal antibody recognizing modification after translation of p53 in a manner specific to a modification site, an antibody microarray comprising the antibody immobilized on a substrate, etc. Disclosed is a monoclonal antibody which reacts specifically with a peptide consisting of an amino acid sequence of at least 6 consecutive amino acids containing a predetermined amino acid residue of the amino acid sequence represented by SEQ ID NO: 1, wherein the amino acid residue is phosphorylated or acetylated, or with a peptide having one to several arbitrary amino acids added to the above peptide, but does not react with the above peptide which is not phosphorylated or acetylated.Type: GrantFiled: March 31, 2006Date of Patent: November 22, 2011Assignees: National University Corporation, Hokkaido University, Genenet Co., Ltd.Inventors: Kazuyasu Sakaguchi, Yoshiro Chuman, Yasuo Akebiyama, Miho Matsukizono, Maki Watanabe, Junichi Tsutsumi
-
Publication number: 20110268745Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce clotting time in (a) human FVIII-deficient plasma and/or (b) human whole blood. Such antibodies have utility in the treatment of bleeding disorders and in the stimulation of blood clotting.Type: ApplicationFiled: December 18, 2009Publication date: November 3, 2011Applicant: Novo Nordisk A/SInventors: Ida Hilden, Jes Thorn Clausen
-
Publication number: 20110236455Abstract: The present invention relates to the identification of novel regulators of the innate immune system, in particular the complement system. More particularly, the present invention relates to specific C5 convertase inhibitors. These novel inhibitors are particularly useful for treating inflammatory diseases involving the complement system. In a first aspect, the present invention focuses on the use of CFHR proteins and functional fragments or functional derivatives thereof for preventing inflammatory reactions. In a further aspect, the present invention focuses on the use of said CFHR proteins for inactivating complement activation during transplantation and dialysis and for coating devices which come into contact with blood or body fluids, in particular implants. The invention furthermore provides a pharmaceutical composition comprising functional CFHR protein in combination with functional factor H.Type: ApplicationFiled: September 28, 2009Publication date: September 29, 2011Inventors: Peter Zipfel, Christina Skerka, Reinhard Wallich
-
Patent number: 8026345Abstract: The invention pertains to methods for measuring different forms of human adiponectin that are present in human plasma/serum, and more specifically methods are based on an ELISA assay that utilizes different monoclonal antibodies directed against adiponectin, in combination with different polyclonal antibodies directed against different domains of human adiponectin. The invention also provides unique isoforms of adiponectin and antibodies thereto, including polyclonal and monoclonal antibodies.Type: GrantFiled: January 2, 2008Date of Patent: September 27, 2011Assignee: Hoffmann-La Roche Inc.Inventors: Charles Roger Burghardt, Jarema Peter Kochan, Erik Roy Rasmussen
-
Patent number: 8008024Abstract: The invention involves assays, diagnostics, kits, and assay components for determining levels of K41-glycated CD59 in subjects. Treatments for subjects based upon levels of K41-glycated CD59 also are provided.Type: GrantFiled: October 3, 2008Date of Patent: August 30, 2011Assignee: President and Fellows of Harvard CollegeInventor: Jose Halperin
-
Patent number: 7999081Abstract: The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterised by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies and to the therapeutic use of both polypeptide and nucleotide sequences, in particular for the therapy of diseases involving tissue damage deriving from uncontrolled activation of the complement system.Type: GrantFiled: July 10, 2003Date of Patent: August 16, 2011Assignee: Adienne SRLInventors: Francesco Tedesco, Roberto Marzari
-
Patent number: 7999082Abstract: Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.Type: GrantFiled: February 10, 2005Date of Patent: August 16, 2011Assignees: National Jewish Medical and Research Center, MUSC Foundation for Research Development, The Regents of the University of ColoraodoInventors: Vernon Michael Holers, Joshua M. Thurman, Christian Taube, Erwin W. Gelfand, Gary Steven Gilkeson
-
Patent number: 7981632Abstract: The present invention relates to sequentially arranged streptavidin-binding binding modules which may in particular be used as affinity tags. The affinity tags comprise at least two individual modules capable of mediating avidic binding to streptavidin.Type: GrantFiled: December 17, 2001Date of Patent: July 19, 2011Assignee: IBA GmbHInventor: Thomas Schmidt
-
Patent number: 7981672Abstract: The purpose of the invention is to provide an antibody which recognizes OPN N-half but does not recognize the full-length OPN, and its use. A monoclonal antibody which is characterized in that it recognizes a protein or polypeptide in which the C-terminal amino acid sequence is YGLR (SEQ ID NO: 1) and it substantially does not recognize a protein or polypeptide which has an amino acid sequence of YGLR outside of the C-terminal, as well as a method for measuring OPN N-half utilizing the said antibody, a method for diagnosing diseases relating to OPN N-half, a method for judging the severity of said disease, and a method for treating said diseases, are provided.Type: GrantFiled: September 11, 2007Date of Patent: July 19, 2011Assignee: Immuno-Biological Laboratories Co., Ltd.Inventors: Hiroko Kobayashi, Masahiro Hasegawa, Tsutomu Seito
-
Patent number: 7959917Abstract: This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma.Type: GrantFiled: February 15, 2008Date of Patent: June 14, 2011Assignee: MedImmune LimitedInventors: Duncan Cochrane, Suzanne Cohen, Claire Louise Dobson, Per-Olof Eriksson, Karin Von Wachenfeldt, Phillip David Monk
-
Patent number: 7943135Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: GrantFiled: June 29, 2006Date of Patent: May 17, 2011Assignee: Genentech, Inc.Inventors: Michael S. C. Fung, William N. C. Sun, Cecily R. Y. Sun
-
Patent number: 7943745Abstract: A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided.Type: GrantFiled: April 5, 2007Date of Patent: May 17, 2011Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Tomoyuki Tahara, Yoshikatsu Kanai, Hitoshi Endou, Shiro Kataoka, Kazumasa Hasegawa, Tetsuya Yoshino
-
Patent number: 7939288Abstract: The invention relates to a method for determining a factor XIII deficiency, a method for determining a fibrinogen deficiency, and a method for differentiating between a factor XIII deficiency and a fibrinogen deficiency by means of thrombelastographic techniques. On the basis of the evaluation of the thrombelastographic parameters, a rapid and a selective substitution of factor XIII and/or of fibrinogen in deficiency states is possible.Type: GrantFiled: February 6, 2006Date of Patent: May 10, 2011Assignee: CSL Behring GmbHInventors: Erhardt Wrabetz, Hubert Metzner, Wolfgang Korte
-
Patent number: 7935341Abstract: Disclosed are antibodies and antigen-binding fragments that bind to a complementary peptide having an amino acid sequence that is encoded by the complement of a nucleotide sequence encoding thrombin or a portion thereof. Such antibodies and antigen-binding fragments can be agonists or antagonists of thrombin receptor-mediated events. Also disclosed are methods of using the agonist antibodies and antigen-binding fragments of the invention to activate the non-proteolytically activated thrombin receptor (NPAR) in a subject in need of such treatment. In addition, methods of using the antagonist antibodies and antigen-binding fragments of the invention to inhibit activation of the NPAR in a subject in need of such treatment are disclosed.Type: GrantFiled: September 14, 2006Date of Patent: May 3, 2011Assignee: Orthologic Corp.Inventors: Darrell H. Carney, John S. Bergmann, Gerald M. Fuller
-
Patent number: 7919255Abstract: A means of measuring and monitoring skeletal growth rate using a plasma analyte, amino-terminal C-type natriuretic peptide (NT-CNP). Plasma NT-CNP concentrations reflect the potential for further growth of the immature skeleton. Measurement of plasma NT-CNP in a subject, when related to the mean of an appropriate age and gender matched set of control subjects, provides an index of the severity of a growth disorder not otherwise available and facilitates diagnosis in children with undetected osteo-chondrodysplasias or other intrinsic disorders of the growth plate. The invention also provides a means of detecting and monitoring potentially harmful effects of drugs and other factors on skeletal growth long before they are evident using current methods in clinical practice.Type: GrantFiled: June 17, 2004Date of Patent: April 5, 2011Assignee: Otago Innovation LimitedInventors: Timothy Charles Ramsey Prickett, Eric Arnold Espiner, Arthur Mark Richards, Timothy Grant Yandle, Michael Gary Nicholls
-
Patent number: 7915004Abstract: Method for determining the level of PTX3 protein in a sample of a biological fluid; hybridoma capable of producing a rat anti-PTX3 monoclonal antibody where said hybridoma is selected from the group comprising MNB10 and Pen-3; specific anti-PTX3 rat monoclonal antibody selected from the monoclonal antibodies produced by the hybridomas MNB10 and Pen-3; kit for determining the level of PTX3 protein in a biological fluid wherein the said kit includes a rat anti-PTX3 monoclonal antibody.Type: GrantFiled: April 27, 2005Date of Patent: March 29, 2011Assignee: Farma Development S.r.l.Inventors: Alberto Mantovani, Giuseppe Peri
-
Patent number: 7910106Abstract: The invention describes the use of an antibody specific for serum amyloid P component, for the treatment or prophylaxis of amyloidosis, and the use of a compound which depletes serum amyloid P component from the circulation in combination with an antibody specific for serum amyloid P component.Type: GrantFiled: December 30, 2008Date of Patent: March 22, 2011Assignee: Pentraxin Therapeutics Ltd.Inventor: Mark B. Pepys
-
Patent number: 7901900Abstract: The present invention provides an antibody prepared using a peptide as an antigen, the peptide having 8 to 30 amino acid residues selected from an amino acid sequence at positions 1 to 68 of human high-molecular-weight CD14, or an antibody that binds to a peptide having a specific amino acid sequence at a position among the positions 1 to 68. An assay kit for human low-molecular-weight CD14 using the antibody and an assay method of the present invention, preferably a sandwich method, are able to quantitatively or qualitatively determine human low-molecular-weight CD14 with high sensitivity and specificity in a simple manner, so that they are useful for the diagnosis of a patient suffering from sepsis.Type: GrantFiled: December 4, 2007Date of Patent: March 8, 2011Assignee: Mochida Pharmaceutical Co., Ltd.Inventors: Shoji Furusako, Kamon Shirakawa
-
Publication number: 20110039353Abstract: The present invention relates to the use of at least one partner for binding to an aldehyde derivative resulting from the peroxidation of lipids in protein-bound form, for instance to 4-hydroxy-2-nonenal, to 4-hydroxy-2-hexenal or to malondialdehyde, for the detection of ischemia-modified albumin (IMA) in a biological sample.Type: ApplicationFiled: March 10, 2009Publication date: February 17, 2011Applicant: BIOMERIEUXInventors: Christine Des Rosiers, Colette Jolivet-Reynaud, Jerome Martinez
-
Patent number: 7883705Abstract: To provide an antibody against FGF23 and a pharmaceutical composition such as a preventive or therapeutic agent which can prevent or treat by suppressing an action of FGF23 by using the antibody. An antibody or its functional fragment against human FGF23 produced by hybridoma C10 (Accession No. FERM BP-10772).Type: GrantFiled: February 13, 2008Date of Patent: February 8, 2011Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Yuji Yamazaki, Itaru Urakawa, Hitoshi Yoshida, Yukiko Aono, Takeyoshi Yamashita, Takashi Shimada, Hisashi Hasegawa
-
Patent number: 7884198Abstract: The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo. The mouse monoclonal antibody has been humanized and the resulting chimeric antibody provides a previously unknown means to diagnose, prevent and/or treat infections caused by gram positive bacteria bearing lipoteichoic acid. This invention also encompasses a peptide mimic of the lipoteichoic acid epitope binding site defined by the monoclonal antibody. This epitope or epitope peptide mimic identifies other antibodies that may bind to the lipoteichoic acid epitope. Moreover, the epitope or epitope peptide mimic provides a valuable substrate for the generation of vaccines or other therapeutics.Type: GrantFiled: December 23, 2008Date of Patent: February 8, 2011Assignees: The Henry M. Jackon Foundation for the Advancement of Military Medicine, Altor Bioscience CorporationInventors: Gerald Walter Fischer, Richard F. Schuman, Hing Wong, Jeffrey R. Stinson
-
Patent number: 7872104Abstract: This invention concerns an antibody which binds with high affinity to human single-chain intact, i.e. not internally cleaved, mature and/or zymogen forms of prostate specific antigen (SCINT PSA). The antibody does not bind to a nicked PSA (PSA-N), wherein said PSA-N has been formed by internal peptide bond cleavage(s) of SCINT PSA resulting in two-chain or multi-chain PSA. This invention further concerns an immunoassay and a method for differentiating patients with cancer of the prostate (PCa) from patients with benign prostatic hyperplasia (BPH) and/or healthy male subjects without PCa, patients with aggressive PCa from patients with indolent PCa and/or patients with clinically localized and/or organ confined PCa from patients with extraprostatic extension of PCa and/or PCa with metastatic spread to lymph nodes or bone marrow using said antibody.Type: GrantFiled: September 26, 2001Date of Patent: January 18, 2011Assignee: Arctic Partners Oy ABInventors: Kim Pettersson, Hans Lilja, Timo Lövgren, Pauliina Niemelä
-
Patent number: 7858758Abstract: Certain monoclonal antibodies are able to detect urinary trypsin inhibitors (UTIs) that are characteristic of disease in humans. In particular, the UTIs include AMBK, Bikunin, Uristatin, Uristatin-1, Uristatin-2, as defined herein, also including the fragments and aggregates thereof.Type: GrantFiled: June 24, 2008Date of Patent: December 28, 2010Assignee: Siemens Healthcare Diagnostics, Inc.Inventors: Michael J. Pugia, Linda Anderson-Mauser, Solomon H. Murphy, Ronald G. Sommer, Shannon Gleason
-
Patent number: 7858090Abstract: A fibronectin type III (Fn3) polypeptide monobody, a nucleic acid molecule encoding said monobody, and a variegated nucleic acid library encoding said monobody, are provided by the invention. Also provided are methods of preparing a Fn3 polypeptide monobody, and kits to perform said methods. Further provided is a method of identifying the amino acid sequence of a polypeptide molecule capable of binding to a specific binding partner (SBP) so as to form a polypeptide:SSP complex, and a method of identifying the amino acid sequence of a polypeptide molecule capable of catalyzing a chemical reaction with a catalyzed rate constant, kcat, and an uncatalyzed rate constant, kuncat, such that the ratio of kcat/kuncat is greater than 10.Type: GrantFiled: April 24, 2006Date of Patent: December 28, 2010Assignee: Novartis International Pharmaceutical Ltd.Inventor: Shohei Koide
-
Patent number: 7846673Abstract: Disclosed herein is the discovery of a soluble MN/CA IX (s-CA IX) found in body fluids, such as, urine and serum. Soluble CA IX comprises the extracellular domain of CA IX or portions thereof. The predominant s-CA IX species is the extracellular domain comprising a proteoglycan-like (PG) domain and carbonic anhydrase (CA) domain, and having a molecular weight of about 50/54 kilodaltons. Diagnostic/prognostic methods for precancer/cancer that detect or detect and quantitate s-CA IX in body fluids, are described. Also disclosed is the coexpression of CA IX and HER-2 that provides potentially synergistic diagnostic/prognostic and therapeutic strategies for precancer/cancer. Further disclosed are new MN/CA IX-specific antibodies generated from MN/CA IX-deficient mice, useful diagnostically/prognostically and therapeutically for cancer/precancer.Type: GrantFiled: August 19, 2004Date of Patent: December 7, 2010Assignee: Institute of Virology of the Slovak Academy of SciencesInventors: Jaromir Pastorek, Silvia Pastorekova, Miriam Zatovicova, Jan Zavada, Marta Ortova Gut, Zuzanna Zavadova
-
Patent number: 7829095Abstract: A monoclonal antibody which inhibits the blood clotting factor VII-activating protease and its proenzyme and a blood clotting factor VII-activating protease, stabilized by the addition of said monoclonal antibody, and its proenzyme are described. A suitable monoclonal antibody is produced by hybridoma cell line DSM ACC 2533. The application of the inhibitory, monoclonal antibody in the stabilization of blood clotting preparations and in preparations for reducing the coagulability of the blood is disclosed.Type: GrantFiled: February 7, 2003Date of Patent: November 9, 2010Assignee: CSL Behring GmbHInventors: Juergen Roemisch, Wiegand Lang, Annette Feussner, Gudrun Muth-Naumann, Hans-Arnold Stoehr, Christian Kannemaier, Klaus Preissner, Fumie Nakazawa
-
Patent number: 7829294Abstract: The present invention is directed to a monoclonal antibody against a soluble fibrin, which specifically recognizes a conformation-changed site newly occurred in a C-terminal region of an A?-chain of the soluble fibrin formed through thrombin digestion of fibrinogen. The present invention is also directed to a hybridoma which produces the antibody, an immunological assay method employing the antibody, and a method for evaluating hypercoagulability in a test sample by measuring the soluble fibrin level in the sample with the assay method. Through employment of the monoclonal antibody of the present invention, soluble fibrin on which plasmin has not acted, which reflects exclusively initial hypercoagulability, can be specifically detected.Type: GrantFiled: December 27, 2005Date of Patent: November 9, 2010Assignee: Daiichi Pure Chemicals Co., Ltd.Inventors: Masanao Matsuo, Hiroyuki Ebinuma, Osamu Miyazaki, Kyoko Tanaka, Akiko Suzuki
-
Patent number: 7824876Abstract: A bioaffinity assay for quantitative determination in a sample of free PAPP-A, defined as the pregnancy associated plasma protein A (PAPP-A) that is not complexed to the proform of major basic protein (proMBP), where free PAPP-A is determined either i) as a calculated difference between measured total PAPP-A and measured PAPP-A complexed to proMBP, or ii) by a direct bioaffinity assay measuring only free PAPP-A. Also disclosed is a method for diagnosing an acute coronary syndrome in a person by using as marker either free PAPP-A as such or a ratio free PAPP-A/total PAPP-A, free PAPP-A/PAPP-A complexed to proMBP, or PAPP-A complexed to proMBP/total PAPP-A.Type: GrantFiled: January 19, 2005Date of Patent: November 2, 2010Assignee: Turun YliopistoInventors: Qiu-Ping Qin, Kim Pettersson
-
Patent number: 7807162Abstract: The present invention relates to improved Nanobodies™ against von Willebrand Factor (vWF), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes.Type: GrantFiled: May 19, 2006Date of Patent: October 5, 2010Assignee: Ablynx N.V.Inventor: Karen Silence
-
Patent number: 7807159Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to myostatin, and that function to inhibit myostatin. The invention also relates to human anti-myostatin antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-myostatin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-myostatin antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-myostatin antibodies.Type: GrantFiled: April 24, 2006Date of Patent: October 5, 2010Assignees: Amgen Fremont Inc., Agouron Pharmaceuticals, Inc.Inventors: Eva Rose Chin, Larry L. Green, Chikwendu Ibebunjo, Philip Albert Krasney, Junming Yie, Joseph Zachweija
-
Patent number: 7795403Abstract: The invention relates to antibodies directed against F1+2, to the preparation and use thereof, especially in therapy and diagnosis. The antibodies bind to an epitope on the N-terminal half of the F2 fragment of prothrombin.Type: GrantFiled: November 19, 2004Date of Patent: September 14, 2010Assignee: Siemens Healthcare Diagnostics Products GmbHInventors: Stefan Teigelkamp, Konrad Braun
-
Patent number: 7785594Abstract: The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VII to levels between 40 and 95%. The present invention further disclosed pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures.Type: GrantFiled: August 16, 2004Date of Patent: August 31, 2010Assignee: Life Sciences Research Partners VZWInventors: Jean-Marie Saint-Remy, Marc Jacquemin
-
Patent number: 7777017Abstract: The present invention encompasses monoclonal antibodies that bind to lipoteichoic acid (LTA) of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro. The invention also provides antibodies having human sequences (chimeric, humanized and human antibodies). The invention also sets forth the variable regions of three antibodies within the invention and presents the striking homology between them.Type: GrantFiled: March 13, 2007Date of Patent: August 17, 2010Assignee: Biosynexus IncorporatedInventors: Jeffrey R. Stinson, Richard F. Schuman, James Jacob Mond, Andrew Lees, Gerald Walter Fischer
-
Patent number: 7771720Abstract: The present application relates to compositions of humanized anti-PAI-1 antibodies and antigen-binding fragments thereof which convert PAI-1 to its latent form. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind and neutralize PAI-1 by converting PAI-1 to its latent form or increasing proteolytic cleavage. Another aspect relates to the use of humanized antibodies which inhibit or neutralize PAI-1 for the detection, diagnosis or treatment of a disease or condition associated with PAI-1 or a combination thereof.Type: GrantFiled: September 5, 2008Date of Patent: August 10, 2010Assignee: CisThera, Inc.Inventors: Donald E. Staunton, Maximiliano Vasquez
-
Patent number: 7771724Abstract: The invention relates to the adhesion of platelet GpIb? to strand ?3 of domain A1 of von Willebrand factor (vWF), the strand ?3 comprising amino acid residues at amino acid position 560-566 and/or a functional part or equivalent thereof, the platelet GpIb?, the GpIb? region comprising an amino acid sequence corresponding to a beta-switch loop of platelet GpIb?, comprising amino acid residues at amino acid position 227-242 and/or a functional part or equivalent thereof. The invention provides a method of interfering with adhesion of blood platelets to vWF that includes modulating adhesion. The invention further provides proteinaceous compounds, antibodies, medicaments and pharmaceutical compositions to that end. The invention also provides means and methods to increase platelet adhesion by topical application of a compound increasing platelet adhesion.Type: GrantFiled: February 7, 2005Date of Patent: August 10, 2010Assignee: Ablynx N.V.Inventors: Eric Geert Huizinga, Philip Gerrit de Groot, Shizuko Tsuji, Roland Antonius Paulus Romijn, Marion Eveline Schiphorst, Jan Johannes Sixma, Piet Gros
-
Patent number: RE42324Abstract: The present invention relates to a novel drug candidate having a potential for universal therapy of allergy and asthma. The invention provides a Fab (antibody fragment), having the following characteristics: a) inhibits the IgE-Fc?RI interaction; b) binds to free and cell-bound IgE; and c) is non-anaphylactic.Type: GrantFiled: April 9, 2010Date of Patent: May 3, 2011Assignee: Phadia ABInventors: Sylvia Laffer, Erik Hogbom, Kenneth H. Roux, Jonas Adriansson, Wolfgang R. Sperr, Peter Valent, Dietrich Kraft, Hans Grönlund, Rudolf Valenta